Ariad Pharmaceuticals: Is An Acquisition Coming?
On Friday, Bloomberg broke a story stating that Ariad Pharmaceuticals and Baxalta were in the midst of acquisition talks. The idea here is that Baxalta wants to purchase Ariad Pharmaceuticals to get hold of the work they’ve been doing in the ever-growing oncology space. While there is no clear deal on the table as of yet, investors got excited pushing Ariad Pharmaceuticals up astronomically on Friday. Currently, ARIA is trading at a loss for the day as talks continue. However, considering the research I’ve done on the topic, the acquisition seems like something that is highly likely to actually happen. So if you’re looking for a strong opportunity, you may want to keep a close eye on this situation as it unfolds.
MannKind Follows A Bearish Trend: Why It Won’t Last Long
MannKind Corporation (NASDAQ: MNKD)
MannKind corporation is having a rough day in the market today. Currently (1:23), the stock is trading at $3.85 per share after a loss of 1.89% so far today. However, I don’t think that declines are likely to last for a few reasons. First and foremost, the stock is trading incredibly close to support insinuating that there is very little downside risk at the moment. Also, we’ve heard quite a bit of news about MNKD recently and most of it has been positive. For example, the company is nearing regulatory approval in Europe, working in Asia for the same, Afrezza production has increased, and the company is testing new medications using its proprietary technology. All in all, I think MNKD is a great stock that’s likely to climb moving forward!
The Medicines Company Is Up On Positive Phase 1 Data
The Medicines Company (NASDAQ: MDCO)
The Medicines Company is having an incredible day in the market today – currently (1:26) trading at $39.84 per share after a gain of 18.43%. The gains we’re seeing today are the result of positive Phase 1 data from the company’s study looking into cholesterol control. The data released today shows that the company’s experimental drug, known as ALN-PCSsc, is proving to be effective in reducing bad cholesterol. As a matter of fact, the study showed a reduction of up to 83% in LDL-C after administration of the drug. Following the data release, MDCO’s VP and global director had the following to say…
“We imagine that ALN-PCSsc has the potential to open new innovation horizons with patients, providers, and payers by linking the temporal cycle of LDL-C monitoring with administration therapy,”
All in all, the data was overwhelmingly positive leading to the increase in the value of the stock. However, it’s important to remember that market movements tend to happen through a series of overreactions. Therefore, I’m expecting to see slight declines tomorrow before upward movement continues. Nonetheless, the overall trend moving forward should be positive.
Twitter Climbs On Analyst Upgrade
Twitter Inc (NYSE: TWTR)
Finally, Twitter is having a great day in the market today after analysts at SunTrust made the decision to upgrade the stock from a “Neutral” to a “Buy” rating, offering a target price of $38. In a research report leading to the upgrade, analyst Robert Peck outlined the fact that he expects the management shaekup to come to an end relatively soon and several catalysts to come. Currently (1:34), TWTR is trading at $28.04 after a gain of 4.47% so far today. While I do see upside potential, I still think there’s a bit of downside risk. So, if you plan to move on this, make sure to move with caution!